The hardest part of studying exosomes is finding them. The tiny, cargo-laden vesicles shed by cells are a treasure trove for diagnostics and drug delivery, but getting enough of them, intact and pure, from a sample of blood or saliva is a slow, messy, and notoriously inconsistent chore. Hermes Biosciences, a new San Francisco-based tools company, is betting that a simple, hands-off benchtop machine can change that calculus for thousands of academic and clinical labs. They have just raised a $6 million seed round, led by Genoa Ventures, to get their first commercial instrument out the door next year [GenomeWeb, Nov 2025].
A Wedge Against the Centrifuge
The company’s wedge is straightforward: replace the complex, multi-step ultracentrifugation workflow with a single automated box. Hermes claims its instrument, which processes biofluids and cell culture media directly, not only automates the isolation but does so with a yield nearly ten times higher than ultracentrifugation and other commercial kits [Business Wire, Nov 2025].
The Founder's Track Record
Hermes is a co-creation of venture studio General Inception and Professor Utkan Demirci of Stanford University. Demirci has a track record of spinning out companies, having co-founded DxNow, Zymot, LevitasBio, and others [Perplexity Sonar Pro Brief].
The Market's Growing Appetite
Analysts project the exosome market to grow from around $700 million to over $2 billion by 2030 [Mordor Intelligence]. The fastest-growing segment within that is microfluidics-based isolation, the technical approach Hermes is banking on [Towards Healthcare].
The Competitive Landscape
Hermes is not entering a vacuum. The field for exosome isolation tools includes established players like NanoView Biosciences and Everest Biolabs [Perplexity Sonar Pro Brief]. The competitive moat will be built on yield, ease of use, and data quality.
The Road to 2026
The next twelve months are a sprint to a product launch. The $6 million seed round is the fuel. The key milestones are clear: finalize the instrument design, place early units with key opinion leaders, and begin generating the third-party data that will be the currency of any serious sales conversation in this market.
Sources
- [GenomeWeb, Nov 2025] Exosome Isolation Startup Hermes Biosciences Raises $6M in Seed Funding | https://www.genomeweb.com/business-news/exosome-isolation-startup-hermes-biosciences-raises-6m-seed-funding
- [Business Wire, Nov 2025] Hermes Biosciences Raises Seed Funding to Make Extracellular Vesicles a Practical Tool for Precision Medicine | https://www.businesswire.com/news/home/20251118339710/en/Hermes-Biosciences-Raises-Seed-Funding-to-Make-Extracellular-Vesicles-a-Practical-Tool-for-Precision-Medicine
- [Perplexity Sonar Pro Brief] Product, team, and market details from web-grounded research
- [Mordor Intelligence] The Exosomes Market size is estimated at USD 0.71 billion in 2025, and is expected to reach USD 2.21 billion by 2030 | Source date unknown
- [Towards Healthcare] By workflow, the microfluidics-based isolation segment is expected to register the fastest expansion during 2025-2034 | Source date unknown